Posts by Rathna Veeramachaneni, Ph.D.
Prior to KCAS Bio, Rathna worked at Celerion (NE, USA) and Pfizer (NY, USA) developing quantitative methods for small and large molecules both in the CRO and Pharma space. Rathna received her Ph.D. from Duquesne University (PA, USA) working on Crosslinking combined with qualitative proteomic mass spectrometry to determine the structure of membrane ion channels in multiple conformational states. Rathna has significant expertise in hybrid LC-MS/MS both at the protein and peptide level.
Blogs
Antibody-drug conjugates (ADCs) have been conventionally developed for a wide range of oncological applications since the first ADC approval in 2000 by the FDA. Typically, an ADC consists of three main components: antibody, linker conjugate, and therapeutic drug (payload). The mechanism of an ADC involves the antibody binding to a specific…